Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa-Reference-Cited by-同舟云学术

Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa

Published:2004-01 Issue:1 Volume:27 Page:17-24
ISSN:0362-5664
Container-title:Clinical Neuropharmacology
language:en
Short-container-title:Clinical Neuropharmacology

Author:

Almeida Luis,Vaz-da-Silva Manuel,Silveira Pedro,Falcão Amilcar,Maia Joana,Loureiro Ana,Torrão Leonel,Machado Rita,Wright Lyndon,Soares-da-Silva Patrício

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Clinical Neurology,Pharmacology

Reference33 articles.

1. The Natural History of Parkinson’s Disease in the Pre-Levodopa and Post-Levodopa Eras

2. An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment

3. Pharmacokinetics of Levodopa

4. The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson??s Disease

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of Non-Nitrocatechol Pan and Isoform Specific Catechol-O-methyltransferase Inhibitors and Substrates;ACS Chemical Neuroscience;2011-12-08

2. In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in Göttingen minipigs;Journal of Pharmacy and Pharmacology;2011-04-28

3. A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease;CNS Neuroscience & Therapeutics;2010-11-09

4. Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor;Current Medical Research and Opinion;2010-03-15

5. PROBLEMS WITH THE PRESENT INHIBITORS AND A RELEVANCE OF NEW AND IMPROVED COMT INHIBITORS IN PARKINSON'S DISEASE;INT REV NEUROBIOL;2010